Stephen (Steve) B. Maebius is a partner and intellectual property lawyer with Foley & Lardner LLP. He has led teams within Foley handling a variety of different kinds of IP work, including IP due diligence reviews, infringement and validity opinions, international portfolio management, licensing, litigation with parallel inter partes reviews, reexaminations and interferences, and pharmaceutical patent term extensions. Two IP transactions in which Mr. Maebius has participated were awarded "Deal of Distinction" status by the Licensing Executives Society. He is a former member of the firm’s Management Committee and former chair of the Intellectual Property Department. Prior to becoming a lawyer, he was a patent examiner in the Biotechnology Group of the U.S. Patent & Trademark Office.
Representative Matters
- Lead counsel in successful defense of 6 Inter Partes Reviews filed by generic petitioners against a family of Orange Book-listed pharmaceutical patents covering a $1B controlled release product with parallel Hatch-Waxman litigation (IPR2013-00368, IPR2013-00371, and IPR2013-00372 - instituted but all claims found patentable in final written decision; IPR2015-01777, IPR2015-01778, and IPR2015-01782 - not instituted)
- Prosecuted product-by-process patent listed in Orange Book that was upheld as valid and infringed in United Therapeutics v. Sandoz, 2014 U.S. Dist. LEXIS 121573 (D.N.J. Aug. 29, 2014)
- Co-counsel for successful petitioner in Inter Partes Review filed against patent asserted in litigation against LED client (IPR2012-00005; decision affirmed on appeal)
- Takeda Pharmaceutical Co. Ltd. v. John Doll (Fed. Cir. 2009) – co-counsel in precedential 2-1 decision remanding a double patenting rejection arising from patent reexamination (all claims confirmed to be patentable upon remand to the Patent Office)
- Goldenberg & Immunomedics v. Cytogen & C.R. Bard (Fed. Cir. 2004) – co-counsel on appeal in reversal of summary judgment in client's favor in precedential 2-1 decision on doctrine of equivalents issue
More Legal and Business Bylines From Stephen B. Maebius
- Revisiting FDA’s Original Guidance on Orange Book Listability in Light of Heightened FTC Scrutiny - (Posted On Friday, November 17, 2023)
- Wondering if Your Digital Health Product or Service is Subject to FDA Regulations? - (Posted On Monday, November 28, 2022)
- PTAB’s Motion to Amend Pilot Program: Review of Initial Results - (Posted On Wednesday, August 19, 2020)
- PTAB - 2019 Year in Review - (Posted On Friday, January 24, 2020)
- District Court Sheds Light on Scope of IPR Estoppel - (Posted On Friday, September 13, 2019)
- New Estoppel Concern For Petitioners Raised In BTG v. Amneal - (Posted On Monday, February 18, 2019)
- New Estoppel Concern For Petitioners Raised in BTG v. Amneal - (Posted On Saturday, February 16, 2019)
- PTAB Boardside Chat Provides Further Details About New Amendment Procedure - (Posted On Thursday, November 08, 2018)
- USPTO Announces Proposal To Facilitate Amendments In AIA Challenges - (Posted On Friday, October 26, 2018)
- Revamped PTAB Trial Practice Guide Holds Surprises - (Posted On Monday, August 13, 2018)